CD11b+Ly6C++Ly6G- cells show distinct function in mice with chronic inflammation or tumor burden

BMC Immunology

Volumn 13, Issue , 2012, Pages

  Källberg, Eva ^a   Stenström, Martin ^a   Liberg, David ^a   Ivars, Fredrik ^a   Leanderson, Tomas ^a  

^a Active Biotech Research AB   (Sweden)

Author keywords

Inflammation; Myeloid cells; Suppression; T cells; Tumor

Indexed keywords

ARGINASE 1; CALGRANULIN B; CD11B ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL GROWTH; CELL ISOLATION; CELL POPULATION; CELL STIMULATION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; COCULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GRANULOMA; IMMUNOREGULATION; LYMPHOCYTE; LYMPHOMA; MOUSE; NONHUMAN; PLASTICITY; POLYMERASE CHAIN REACTION; SPLEEN; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, LY; ARGINASE; CALGRANULIN B; CELL PROLIFERATION; CHRONIC DISEASE; FEMALE; INFLAMMATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; SPLEEN; T-LYMPHOCYTES; TERPENES; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84870892487     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-13-69     Document Type: Article

References (25)

1. Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003, 24:155-158. 10.1016/S1471-4906(03)00062-0, 12697438.
2. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005, 11:5146-5152. 10.1158/1078-0432.CCR-05-0352, 16033829.
3. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771. 10.1002/art.20631, 15593206.
4. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
5. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. Identification of Human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biology 2009, 7:800-812.
6. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059. 10.1038/nm1622, 17704786.
7. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008, 205:275-285. 10.1084/jem.20070679, 2271015, 18208974.
8. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006, 8:1369-1375. 10.1038/ncb1507, 17128264.
9. Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, Wikstrom P, Bergh A, Roth J, Ivars F, Leanderson T. S100A9 interaction with TLR4 promotes tumor growth. PLoS One 2012, 7:e34207. 10.1371/journal.pone.0034207, 3314596, 22470535.
10. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249. 10.1084/jem.20080132, 2556797, 18809714.
11. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174. 10.1038/nri2506, 2828349, 19197294.
12. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268. 10.1038/nri3175, 22437938.
13. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179. 10.1111/j.1600-065X.2008.00602.x, 18364001.
14. Nacionales DC, Kelly KM, Lee PY, Zhuang H, Li Y, Weinstein JS, Sobel E, Kuroda Y, Akaogi J, Satoh M, et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol 2006, 168:1227-1240. 10.2353/ajpath.2006.050125, 1606560, 16565497.
15. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010, 70:5728-5739. 10.1158/0008-5472.CAN-09-4672, 20570887.
16. Lin SL, Castano AP, Nowlin BT, ML Lupher JS. Duffield: Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009, 183:6733-6743. 10.4049/jimmunol.0901473, 19864592.
17. Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, Zabel MD, Hille A, Priller J, Prinz M. CCR2 + Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009, 132:2487-2500. 10.1093/brain/awp144, 19531531.
18. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244. 10.1182/blood-2007-07-099226, 18272812.
19. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802. 2575748, 18832739.
20. Lu L, Bonham CA, Chambers FG, Watkins SC, Hoffman RA, Simmons RL, Thomson AW. Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol 1996, 157:3577-3586.
21. Dasgupta S, Jana M, Liu X, Pahan K. Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J Biol Chem 2002, 277:39327-39333. 10.1074/jbc.M111841200, 1955480, 12176974.
22. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK, Khoury SJ. CD11b + Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007, 179:5228-5237.
23. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, Heyworth PG, Efron PA, Moldawer LL. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 2011, 17:281-292. 10.1007/s00894-010-0723-7, 3060988, 21085745.
24. Yi H, Guo C, Yu X, Zuo D, Wang XY. Mouse CD11b + Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J Immunol 2012, 189(9):4295-4304. 10.4049/jimmunol.1200086, 23034169.
25. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005, 11:6713-6721. 10.1158/1078-0432.CCR-05-0883, 16166452.